Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 09, 2023

BUY
$1.04 - $1.4 $276,132 - $371,716
265,512 Added 444.03%
325,308 $364,000
Q2 2022

Aug 15, 2022

SELL
$0.67 - $1.4 $120,927 - $252,684
-180,489 Reduced 75.11%
59,796 $79,000
Q1 2022

May 13, 2022

BUY
$1.23 - $3.31 $13,015 - $35,026
10,582 Added 4.61%
240,285 $296,000
Q3 2021

Nov 16, 2021

BUY
$3.36 - $4.62 $21,974 - $30,214
6,540 Added 2.93%
229,703 $956,000
Q2 2021

Aug 16, 2021

BUY
$2.82 - $5.01 $124,426 - $221,056
44,123 Added 24.64%
223,163 $933,000
Q1 2021

May 17, 2021

SELL
$2.92 - $5.07 $40,024 - $69,494
-13,707 Reduced 7.11%
179,040 $811,000
Q4 2020

Feb 16, 2021

BUY
$1.64 - $3.42 $11,809 - $24,627
7,201 Added 3.88%
192,747 $585,000
Q3 2020

Nov 13, 2020

BUY
$2.18 - $2.84 $53,856 - $70,162
24,705 Added 15.36%
185,546 $461,000
Q2 2020

Aug 14, 2020

BUY
$1.83 - $4.06 $267,509 - $593,490
146,180 Added 997.07%
160,841 $457,000
Q3 2019

Nov 08, 2019

SELL
$1.6 - $2.08 $7,793 - $10,131
-4,871 Reduced 24.94%
14,661 $26,000
Q2 2019

Aug 09, 2019

SELL
$1.79 - $3.05 $126,689 - $215,866
-70,776 Reduced 78.37%
19,532 $35,000
Q1 2019

May 14, 2019

BUY
$1.47 - $3.06 $83,213 - $173,220
56,608 Added 167.98%
90,308 $215,000
Q4 2018

Feb 14, 2019

SELL
$2.66 - $15.93 $10,906 - $65,313
-4,100 Reduced 10.85%
33,700 $90,000
Q3 2018

Nov 13, 2018

BUY
$12.07 - $16.0 $49,487 - $65,600
4,100 Added 12.17%
37,800 $588,000
Q2 2018

Aug 08, 2018

BUY
$9.36 - $13.25 $85,176 - $120,575
9,100 Added 36.99%
33,700 $447,000
Q4 2017

Jan 17, 2018

SELL
$8.97 - $23.38 $44,850 - $116,900
-5,000 Reduced 16.89%
24,600 $242,000
Q3 2017

Nov 13, 2017

BUY
$15.22 - $20.03 $450,512 - $592,888
29,600
29,600 $541,000

Others Institutions Holding SELB

About SELECTA BIOSCIENCES INC


  • Ticker SELB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 152,712,992
  • Market Cap $128M
  • Description
  • Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. I...
More about SELB
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.